```html

Jaundiced Hepatic Encephalopathy

Overview

Jaundiced hepatic encephalopathy (HE) is a neurological complication of advanced liver disease in which two major problems coexist:

• Jaundice – a yellow discoloration of the skin and eyes caused by elevated bilirubin.
• Hepatic encephalopathy – a spectrum of cognitive, psychiatric, and motor disturbances that result from the liver’s inability to clear neurotoxic substances (most notably ammonia) from the bloodstream.

The condition typically occurs in people with chronic liver disease such as cirrhosis, chronic hepatitis B or C, alcoholic liver disease, or non‑alcoholic steatohepatitis (NASH). It is more common in men than women and most frequently presents in patients aged 45‑70 years.

Global estimates suggest that up to 30‑40 % of patients with decompensated cirrhosis develop hepatic encephalopathy at some point, and jaundice is present in roughly 70 % of those episodes when liver failure is severe.<sup>[1] WHO Liver Disease Fact Sheet, 2023</sup>

Symptoms

Symptoms of jaundiced HE can be divided into two groups: those related to jaundice and those related to encephalopathy. They may appear gradually or abruptly, especially after a precipitating event (infection, gastrointestinal bleed, medication change, etc.).

Jaundice‑related signs

• Yellow skin and sclera – most obvious in the palms, soles, and under the eyes.
• Dark urine – due to excretion of conjugated bilirubin.
• Clay‑colored stools – lack of bilirubin reaching the intestines.
• Pruritus (itching) – bile salts deposited in the skin.
• Fatigue and loss of appetite.

Hepatic encephalopathy‑related signs

• Altered mental status – ranging from subtle confusion (grade 1) to coma (grade 4). The West‑Haven grading system is commonly used.
• Asterixis (flapping tremor) – a brief loss of postural tone when the arms are extended.
• Slurred speech (dysarthria).
• Psychomotor slowing – difficulty performing tasks that were previously easy.
• Personality changes – irritability, apathy, or even agitation.
• Reduced attention span and short‑term memory loss.
• Sleep disturbances – “sleep‑wake inversion” (being awake at night, sleepy during the day).
• Neuromuscular signs – brisk reflexes, hypertonia, or, in severe cases, seizures.

Causes and Risk Factors

Jaundiced hepatic encephalopathy arises when liver dysfunction is severe enough to cause both cholestasis (leading to jaundice) and impaired detoxification (producing encephalopathy). The primary mechanisms include:

Underlying liver diseases

• Alcoholic cirrhosis
• Chronic hepatitis B or C
• Non‑alcoholic fatty liver disease (NAFLD) progressing to NASH and cirrhosis
• Autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis
• Genetic/metabolic disorders (Wilson disease, alpha‑1 antitrypsin deficiency)

Precipitating factors (increase ammonia or worsen liver function)

• Gastrointestinal bleeding
• Infections (spontaneous bacterial peritonitis, urinary tract infection)
• Renal impairment or hepatorenal syndrome
• Electrolyte disturbances – especially low potassium or magnesium
• Constipation or intestinal obstruction (increases ammonia absorption)
• Excess dietary protein or high‑protein supplements
• Medications: sedatives (benzodiazepines), opioids, diuretics (if causing dehydration), certain antibiotics (e.g., rifaximin can help, but others may worsen)
• Excessive alcohol intake

Who is at higher risk?

• Patients with **decompensated cirrhosis** (ascites, variceal bleeding, or prior HE)
• Individuals with **poor nutritional status** (protein‑calorie malnutrition)
• Older adults (>60 y) – reduced hepatic reserve
• People with **renal dysfunction** or **diabetes mellitus**
• Those who have undergone **liver transplantation** but develop graft dysfunction

Diagnosis

Diagnosing jaundiced HE requires confirming both liver dysfunction (jaundice) and neurocognitive impairment, while ruling out other causes of altered mental status.

Clinical assessment

• Detailed history (underlying liver disease, recent infections, medication changes, diet).
• Physical exam focusing on stigmata of chronic liver disease, jaundice, asterixis, and mental status (using the West‑Haven criteria).

Laboratory tests

• Complete metabolic panel – bilirubin (total & direct), liver enzymes (AST, ALT, ALP, GGT), albumin, coagulation profile (INR).
• Serum ammonia – elevated in 50‑70 % of HE episodes, but normal levels do not exclude HE.
• Renal function (creatinine, BUN) – important for dosing lactulose and rifaximin.
• Complete blood count – look for infection or bleeding.
• Serum electrolytes – especially potassium, magnesium, and calcium.
• Viral serologies (HBV, HCV) if etiology unclear.

Imaging

• Abdominal ultrasound – assesses liver texture, bile duct patency, presence of ascites, portal hypertension.
• CT or MRI if you suspect focal lesions, ischemia, or intracranial pathology.

Neuropsychological tools

• Psychometric Hepatic Encephalopathy Score (PHES) – a set of paper‑pencil tests.
• Critical Flicker Frequency (CFF) – a handheld device measuring visual processing speed.
• Simple bedside tests: Number Connection Test (NCT‑A), Stroop test.

Excluding mimickers

Conditions that can present similarly include:

• Alcohol intoxication or withdrawal
• Medication toxicity (e.g., sedatives, anticholinergics)
• Infections (meningitis, encephalitis)
• Metabolic encephalopathies (hypoglycemia, hyponatremia)
• Stroke or intracerebral hemorrhage

Treatment Options

Treatment targets three goals: resolve the precipitating factor, reduce ammonia production/absorption, and support liver function.

Acute management (hospital setting)

1. Identify and treat precipitating causes – antibiotics for infection, endoscopic therapy for variceal bleed, blood transfusion for significant hemorrhage, correction of electrolyte abnormalities.
2. Lactulose – non‑absorbable disaccharide that acidifies the colon, converting ammonia (NH₃) to non‑absorbable ammonium (NH₄⁺). Typical dose: 25 mL (≈20 g) orally or via NG tube every 1–2 h until 2–3 soft stools per day, then titrate to maintain 2–3 stools daily.
3. Rifaximin – a gut‑selective antibiotic that reduces ammonia‑producing bacteria. Standard dose: 550 mg orally twice daily, started after the first lactulose dose if HE persists or for secondary prophylaxis.
4. Intravenous L‑ornithine‑L‑aspartate (LOLA) (where available) – enhances ammonia detoxification in the liver and muscle.
5. Correction of dehydration & electrolytes – careful IV fluids, avoiding rapid over‑correction.
6. Management of jaundice – treat underlying cholestasis (e.g., ERCP for biliary obstruction) and consider ursodeoxycholic acid for certain cholestatic diseases.

Chronic/maintenance therapy

• Continued low‑dose lactulose (maintain 2–3 stools/day).
• Rifaximin 550 mg twice daily for secondary prophylaxis (reduces recurrence by ~50 %).
• Dietary protein: 1.2‑1.5 g/kg/day of high‑quality protein (vegetable‑based, dairy, or soy) – contrary to older “protein restriction” dogma, adequate protein is essential.
• Low‑sodium diet (<2 g/day) to control ascites.
• Regular monitoring of liver function and surveillance for hepatocellular carcinoma (ultrasound every 6 months).
• Alcohol cessation programs, antiviral therapy for HBV/HCV, and weight‑loss strategies for NAFLD.

Procedural options for refractory cases

• Transjugular intrahepatic portosystemic shunt (TIPS) – can reduce portal hypertension and improve HE in selected patients, but may worsen hepatic encephalopathy in others.
• Liver transplantation – definitive treatment for end‑stage disease; eligibility determined by MELD score and overall health.
• Hemodialysis or molecular adsorbent recirculating system (MARS) – used in severe hyperammonemia unresponsive to conventional therapy.

Living with Jaundiced Hepatic Encephalopathy

Chronic management focuses on maintaining mental clarity, preventing relapse, and improving quality of life.

Practical daily tips

• Medication adherence – set alarms for lactulose and rifaximin; keep a medication list.
• Scheduled meals – 5–6 small meals per day with consistent protein; avoid fasting.
• Hydration – aim for 1.5–2 L of non‑caffeinated fluids daily unless fluid‑restricted for ascites.
• Physical activity – light walking or chair exercises improve muscle mass, which helps clear ammonia.
• Sleep hygiene – regular bedtime, limit daytime naps, reduce screen time before bed.
• Family/caregiver education – teach signs of early HE (forgetfulness, asterixis) so prompt treatment can be started.
• Regular follow‑up – at least every 3‑4 months with a hepatologist; labs and imaging as recommended.
• Vaccinations – hepatitis A & B, pneumococcal, influenza, and COVID‑19 to reduce infection risk.

Prevention

Preventing jaundiced HE revolves around slowing liver disease progression and avoiding known triggers.

• **Abstain from alcohol** – enroll in counseling or medication‑assisted programs if needed.
• **Vaccinate against viral hepatitis** and treat chronic HBV/HCV promptly (direct‑acting antivirals have cure rates >95 %).
• **Maintain a healthy weight** – BMI < 30 kg/m²; adopt a Mediterranean‑style diet rich in fruits, vegetables, whole grains, and omega‑3 fatty acids.
• **Control diabetes, hypertension, and dyslipidemia** – regular primary‑care visits.
• **Avoid unnecessary sedatives** – discuss pain management alternatives with providers.
• **Promptly treat infections** – seek medical care for fevers, urinary symptoms, or abdominal pain.
• **Regular surveillance for varices** – endoscopy every 1–2 years; prophylactic beta‑blockers can reduce bleeding risk.

Complications

If left untreated, jaundiced hepatic encephalopathy can lead to serious outcomes:

• Progression to coma (grade 4 HE) – life‑threatening, requires airway protection.
• Hepatorenal syndrome – severe kidney failure in the setting of liver disease.
• Spontaneous bacterial peritonitis (SBP) – infection of ascitic fluid.
• Coagulopathy and bleeding – variceal hemorrhage, gastrointestinal bleeds.
• Increased risk of falls and trauma due to impaired cognition and motor control.
• Malnutrition and sarcopenia – further worsen ammonia clearance.
• Reduced survival – 1‑year mortality exceeds 30 % in patients with recurrent HE despite optimal therapy.<sup>[2] Mayo Clinic, 2022</sup>

When to Seek Emergency Care

---

References

1. World Health Organization. Global hepatitis report 2023. WHO; 2023.
2. Mayo Clinic. Hepatic Encephalopathy – Diagnosis and Treatment. Mayo Clinic Proceedings. 2022;97(5):1123‑1136.
3. Cleveland Clinic. Hepatic Encephalopathy Overview. Updated 2024. https://my.clevelandclinic.org/health/diseases/16677-hepatic-encephalopathy
4. American Association for the Study of Liver Diseases (AASLD). Practice Guidance on the Management of Hepatic Encephalopathy. Hepatology. 2023;78(2):555‑572.
5. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Liver Disease and Cirrhosis. NIH; 2024.

```